Vyome Holdings, Inc (HIND) — 10-Q Filings
All 10-Q filings from Vyome Holdings, Inc. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
Vyome Holdings' Net Loss Soars to $9.2M Post-Merger
— Nov 14, 2025 Risk: high
Vyome Holdings, Inc. (HIND) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $9,198,033, a substantial rise fr -
ReShape Lifesciences Narrows Loss Amid Revenue Dip, Eyes Vyome Merger
— Aug 14, 2025 Risk: high
ReShape Lifesciences Inc. (HIND) reported a net loss of $1.156 million for the six months ended June 30, 2025, a significant improvement from the $3.788 million -
ReShape Lifesciences Files Q1 2025 10-Q
— May 20, 2025 Risk: medium
ReShape Lifesciences Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly Obalon Therapeutics Inc., is based in San Clemente, CA. The -
ReShape Lifesciences Files Q3 2024 10-Q
— Nov 14, 2024 Risk: medium
ReShape Lifesciences Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as Obalon Therapeutics Inc., is incorporated in D -
ReShape Lifesciences Q2 2024: Revenue Dip, Asset/Liability Balance
— Aug 14, 2024 Risk: medium
ReShape Lifesciences Inc. filed its 10-Q for the period ending June 30, 2024. The company reported total assets of $1.5 million and total liabilities of $1.5 mi -
ReShape Lifesciences Inc. Files 10-Q for Period Ending March 31, 2024
— May 15, 2024 Risk: low
ReShape Lifesciences Inc. (HIND) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. ReShape Lifesciences Inc. filed a 10-Q report for the period endi
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX